Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. - Wikidata - awgldk - TriplyDB

Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure.

Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure.

http://www.wikidata.org/entity/Q43573505

about

Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease?Cardiac resynchronization therapy in heart failure patients with less severe left ventricular dysfunction Diastolic dysfunction The effects of medications on circulating levels of cardiac natriuretic peptides A reappraisal of loop diuretic choice in heart failure patients Antifailure therapy including spironolactone improves left ventricular energy supply-demand relations in nonischemic dilated cardiomyopathy.High-sensitivity troponin T: a biomarker for diuretic response in decompensated heart failure patients.CB(1) cannabinoid receptor antagonism promotes remodeling and cannabinoid treatment prevents endothelial dysfunction and hypotension in rats with myocardial infarction.Natriuretic Peptide testing in primary care Variability of NT-proBNP and its relationship with inflammatory status in patients with stable essential hypertension: a 2-year follow-up study.Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials.Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney diseas Surrogate end points in heart failure.Natriuretic peptides in the diagnosis and management of heart failure The potential benefits of aldosterone antagonism in Type 2 diabetes mellitus.Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment Genome-wide association analysis of plasma B-type natriuretic peptide in blacks: the Jackson Heart Study.The role of aldosterone in heart failure and the clinical benefits of aldosterone blockade.Variability of NT-proBNP plasma and urine levels in patients with stable heart failure: a 2-year follow-up study.Brain natriuretic peptide and optimal management of heart failure.Brain natriuretic peptide levels and left ventricular functional recovery in a chronic heart failure population.Circulating Aldosterone Levels and Disease Severity in Pulmonary Arterial Hypertension.A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials.Can we use B-type natriuretic peptides to monitor patients with heart failure?Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes.Mineralocorticoid receptor antagonists for heart failure.Updating the role of natriuretic peptide levels in cardiovascular disease.Brain natriuretic peptide-guided therapy in the inpatient management of decompensated heart failure.Mineralocorticoid receptor activation in myocardial infarction and failure: recent advances.Eplerenone for the treatment of cardiovascular disorders.The role of natriuretic peptides as biomarkers for guiding the management of chronic heart failure.Molecular and Digital Biomarker Supported Decision Making in Clinical Studies in Cardiovascular Indications.NT-proBNP and BNP: biomarkers for heart failure management.ANMCO/ELAS/SIBioC Consensus Document: biomarkers in heart failure.Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach.Natriuretic peptides as a prognostic marker and therapeutic target in heart failure.Aldosterone augments endothelin-1-induced cardiac myocyte hypertrophy with the reinforcement of the JNK pathway.Potential beneficial as well as detrimental effects of chronic treatment with lisinopril and (or) spironolactone on isolated hearts following low-flow ischemia in normal and infarcted rats.

P2860

Q24678615-5B4AA1A6-2907-4C1B-B11B-A5D062264F36 Q27002918-E2FCF08E-9963-49E0-BE6B-6E4E359446C5 Q28087715-38E7CB6C-FF69-4FE0-91FC-12D4821FBC48 Q28212913-C8DC9DA0-4299-41DC-AD80-C87CC3AC23E6 Q28258044-DE832458-9983-4A9B-8C48-190820FE6875 Q30619167-249B817C-C250-4481-8B68-4C6880852E14 Q30854596-763C076B-959E-413D-9530-F01BFB7E113B Q30918735-B656F7C6-36C7-435D-AAF2-DEEB926672A4 Q33572286-4A94B8F5-C194-4EC1-A913-C1B7387FD837 Q34181625-A52B3B3E-A390-4DB6-867B-0949D022316C Q34324771-6F548CEC-192E-4D21-848C-43A61D7FF35D Q34364927-4C549F1E-E0DE-46BE-8E70-28CBF639BFA7 Q34462504-BDCD6B0F-BFBB-47C3-A552-177836E8322A Q34564309-A24E7B1C-DDCB-4FB5-9E0A-55E4E236EEFE Q35015563-CC63829D-C752-416B-8F17-5DBF1F53EBCC Q35058628-1B6FFC43-31C2-4F7B-BD6D-A3789C71C3B6 Q35582571-79016207-2FE9-471A-A8C6-15B6D9B61E6B Q35591500-AA8BD66D-CBD6-4A4C-9E5A-6D8AA2D59ED6 Q35706823-BF7CFBA0-A299-45E5-9A12-B347F9E1D278 Q36014073-BA065969-7270-4A08-8DE0-C82FA55420B1 Q36244209-EA227921-372C-4B3D-B289-CEEB5D33EED6 Q36440968-7245630E-5C36-4552-A543-D3AE470FB47E Q36883558-E721A471-A675-4D3A-9674-FFAECBA9276F Q37098407-A941B891-F11F-4A9F-A890-47E20AFF196B Q37344514-98C7EA33-7E0F-4477-BF61-79A15357AAE6 Q37755067-AD8BC9EC-73B5-4DC3-B3D7-0C3A204450E7 Q37889518-10FB41C7-D70F-467E-970B-B8A275C7B840 Q37955919-B395D60E-2CDC-431D-83FD-7B50A2F729D2 Q37959158-8E50459B-6531-442C-A242-98D0D412F930 Q37980254-A55CA011-063D-4A24-BB30-C20F70EACE7C Q38005732-F0D61432-3779-46FA-9276-DE815B89D733 Q38036328-C160E85B-F5D8-40DB-9DB0-A41616ECCCEC Q38063118-970BC1B5-33F2-4814-943F-15147B9B903D Q38815451-398A3FA6-69E6-414C-96AC-D14B7D450552 Q40528924-5F64BF79-CE6E-4173-8F46-7059C39E5FEF Q41083010-92DA4135-BD7A-4209-8E56-5DB21C49C53E Q41845098-46C42A7A-F1BB-4ADB-8932-A6DB7459FF23 Q42832904-F5063B52-A8A6-4874-AB0D-316D1180ECFF Q44075487-CE7FDE31-A78B-49CF-B20D-FD94F5841CB7 Q44653714-EDE8DF80-C938-4176-83AE-AE7F3A8F0504

P2860

Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure.

http://www.wikidata.org/entity/Q43573505

description

2001 nî lūn-bûn

@nan

2001年の論文

@ja

2001年学术文章

@wuu

2001年学术文章

@zh

2001年学术文章

@zh-cn

2001年学术文章

@zh-hans

2001年学术文章

@zh-my

2001年学术文章

@zh-sg

2001年學術文章

@yue

2001年學術文章

@zh-hant

name

Effect of spironolactone on pl ...... with congestive heart failure.

@en

Effect of spironolactone on pl ...... with congestive heart failure.

@nl

type

label

Effect of spironolactone on pl ...... with congestive heart failure.

@en

Effect of spironolactone on pl ...... with congestive heart failure.

@nl

prefLabel

Effect of spironolactone on pl ...... with congestive heart failure.

@en

Effect of spironolactone on pl ...... with congestive heart failure.

@nl

P1433

Q43573505-25B41C97-5767-4535-A924-2963086EB7DE

P1476

Q43573505-A4CCEBC3-B57A-4328-B64E-CACE65650112

P2093

Q43573505-1FAD8D5F-E968-4C5C-BDD1-7DC4EC35573C

Q43573505-2947E308-06EC-49BE-A3A0-F57AE074E348

Q43573505-2CC82D49-94C7-495F-959F-D4CBBBD0E7C1

Q43573505-2D30C3D6-4EE4-406F-BA40-B8CF0E516B3A

Q43573505-2F64E9B3-209C-443B-BCE0-B3178FA2DAB1

Q43573505-48925675-B604-45CA-853C-27E6E8264EDB

Q43573505-5DDE0E9D-3135-49E1-9A53-0FC23AD53860

Q43573505-9BCDDF2D-5819-47DE-BD10-5E59EB465B4A

Q43573505-BB6A67E6-D9FE-4581-836C-61DC5B6C3B4A

Q43573505-BD7EC771-4455-4C9F-A2D7-1C51DB51BAFF

P304

Q43573505-7F8F4641-C3C7-4124-BF63-BC1BD4050C12

P31

Q43573505-D68047B7-B28C-4B48-87C7-C628CED06BB0

P356

Q43573505-E61CAC39-0F1A-4010-B200-D15DC0CFA149

P407

Q43573505-080C5899-AE64-4D02-B6D2-8CD8FCC6CA6A

P433

Q43573505-F8653C7E-11A8-4DF6-A5C1-0AD0DF66BC6E

P478

Q43573505-EC7749DB-6409-492A-A488-47397F7ED51D

P577

Q43573505-94DE0711-058E-4835-9964-FC0688F07BC7

P5875

Q43573505-E7B124C0-7698-4C64-A5F3-C3EACC3639F0

P698

Q43573505-232EA30A-891C-4477-8541-B6E8427A87C5

P921

Q43573505-2E0FCDB1-D0F9-4E2E-BC7F-0163A73089F0

Q43573505-D10F6232-A297-4C44-8735-97A82B31DD6F

Q43573505-DBC7536E-6115-48DE-A849-1897C9C1794F

P356

S0735-1097(01)01116-0

P1433

Journal of the American College of Cardiology

P1476

Effect of spironolactone on pl ...... with congestive heart failure.

@en

P2093

Fujii M

http://www.w3.org/2001/XMLSchema#string

Hayashi M

http://www.w3.org/2001/XMLSchema#string

Kinoshita M

http://www.w3.org/2001/XMLSchema#string

Mabuchi N

http://www.w3.org/2001/XMLSchema#string

Maeda K

http://www.w3.org/2001/XMLSchema#string

Matsui T

http://www.w3.org/2001/XMLSchema#string

Matsumoto T

http://www.w3.org/2001/XMLSchema#string

Ohnishi M

http://www.w3.org/2001/XMLSchema#string

Sawaki M

http://www.w3.org/2001/XMLSchema#string

Tsutamoto T

http://www.w3.org/2001/XMLSchema#string

P304

1228-1233

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0735-1097(01)01116-0

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

37

http://www.w3.org/2001/XMLSchema#string

P577

2001-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12034735

http://www.w3.org/2001/XMLSchema#string

P698

11300427

http://www.w3.org/2001/XMLSchema#string

P921

brain natriuretic peptide